Gene: SLC25A21

89874
ODC|ODC1
solute carrier family 25 member 21
protein-coding
14q13.3
Ensembl:ENSG00000183032 MIM:607571 Vega:OTTHUMG00000140250 UniprotKB:Q9BQT8
NC_000014.9
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.139e-1 (AD)  3.874e-4 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ZNF3830.551
ESR10.538
C14orf390.535
RNF1800.523
EBF30.522
ZNF7900.514
PARPBP0.501
ZNF850.5
LCORL0.5
FNDC3A0.498

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ABHD16B-0.24
LCN1-0.237
HES5-0.217
ADAMTSL5-0.215
BTBD17-0.203
HES6-0.2
GGTLC3-0.199
PYGM-0.197
NEU4-0.193
PRM1-0.192

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB09154Sodium CitrateSmall Molecule68-04-2Approved|InvestigationalTransporter
ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of SLC25A21 mRNA"27291303
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Thimerosal co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A21 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A21 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Thimerosal co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A21 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A21 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 affects the expression of SLC25A21 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of SLC25A21 mRNA21632981|2210060
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of SLC25A21 gene27153756
D000447AldehydesAldehydes results in decreased expression of SLC25A21 mRNA25014914
C487081belinostatbelinostat results in decreased expression of SLC25A21 mRNA27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SLC25A21 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SLC25A21 mRNA22300585
C006780bisphenol Abisphenol A affects the expression of SLC25A21 mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of SLC25A21 mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of SLC25A21 mRNA26079696
C018021cobaltous chloridecobaltous chloride results in decreased expression of SLC25A21 mRNA24386269
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of SLC25A21 mRNA23640034
C118739entinostatentinostat results in decreased expression of SLC25A21 mRNA27188386
D005839GentamicinsGentamicins results in decreased expression of SLC25A21 mRNA22061828
C051890irinotecanirinotecan analog results in decreased expression of SLC25A21 mRNA18927307
C544151jinfukangjinfukang results in decreased expression of SLC25A21 mRNA27392435
D008713MethimazoleMethimazole results in increased expression of SLC25A21 mRNA22504374
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of SLC25A21 mRNA26011545
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of SLC25A21 mRNA"25620056
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of SLC25A21 mRNA25729387
C030110oxaliplatinoxaliplatin results in decreased expression of SLC25A21 mRNA25729387
C046012pentanalpentanal results in decreased expression of SLC25A21 mRNA26079696
D028321Plant PreparationsPlant Preparations results in increased expression of SLC25A21 mRNA18047722
C005556propionaldehydepropionaldehyde results in decreased expression of SLC25A21 mRNA26079696
D011441PropylthiouracilPropylthiouracil results in increased expression of SLC25A21 mRNA22504374
D011794QuercetinQuercetin results in decreased expression of SLC25A21 mRNA21632981
C013672riddelliineriddelliine results in increased expression of SLC25A21 mRNA18047722
D012834SilverSilver results in decreased expression of SLC25A21 mRNA27131904
C016104sodium bichromatesodium bichromate affects the expression of SLC25A21 mRNA22110744
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SLC25A21 mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of SLC25A21 mRNA21215274
D013849Thimerosal"[NOG protein co-treated with Thimerosal co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A21 mRNA"27188386
D014050TolueneToluene affects the expression of SLC25A21 mRNA18653662
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of SLC25A21 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of SLC25A21 mRNA25729387
D014520UrethaneUrethane results in decreased expression of SLC25A21 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A21 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SLC25A21 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of SLC25A21 mRNA24383497|2627250
D014638VanadatesVanadates results in decreased expression of SLC25A21 mRNA22714537
D015215ZidovudineZidovudine results in increased expression of SLC25A21 mRNA24292225

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005310dicarboxylic acid transmembrane transporter activity-IBA21873635  
GO:0015139alpha-ketoglutarate transmembrane transporter activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006554lysine catabolic process-TAS-  
GO:0015742alpha-ketoglutarate transport-IEA-  
GO:0055085transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005743mitochondrial inner membrane-TAS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-6788656Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolismTAS
R-HSA-71064Lysine catabolismTAS
R-HSA-71291Metabolism of amino acids and derivativesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27021816Pathways to smoking behaviours: biological insights from the Tobacco and Genetics Consortium meta-analysis. (2017 Jan)Minica CCMol Psychiatry